QUOTE AND NEWS
Forbes  6 hrs ago  Comment 
Amid a slew of new data demonstrating yet again that PCSK9 inhibitors lower LDL cholesterol-- drastically and in a wide variety of different patient populations-- data from one trial offers the first suggestion that the drugs may in fact improve...
StreetInsider.com  Aug 29  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sanofi+%28SNY%29+Fabry+Disease+Treatment+Receives+FDA+Orphan+Designation/9793403.html for the full story.
FiercePharma  Aug 29  Comment 
What's an OTC drugmaker worth in the race to the top of the consumer healthcare space? Potentially more than $5.3 billion, if that drugmaker is Belgium's Omega Pharma.
Motley Fool  Aug 28  Comment 
Shares of the French biopharma Sanofi have underperformed this year. Here are three reasons why this top healthcare name could rebound soon.
FierceBiotech  Aug 28  Comment 
Amgen has taken another big step in its head-to-head race with Sanofi and Regeneron, filing its application for the prospective cholesterol blockbuster evolocumab and backing it up with more positive data from the latest in a long string of major...
FiercePharma  Aug 27  Comment 
Sanofi has a new North American chief. The French drugmaker has slotted Jez Moulding into the slot Anne Whitaker suddenly vacated a few weeks ago. He'll head up the North American pharma business after serving as SVP of the company's Japan and...
FiercePharma  Aug 27  Comment 
Sleep aids have landed in the safety spotlight recently, with regulatory agencies lowering dosages on some meds to ease side effect worries. But overmedication has its own set of risks, and a new study says those resulted in a doubling of...
Forbes  Aug 27  Comment 
Based on a new study by the Substance Abuse and Mental Health Services Administration (SAMHSA),  estimated emergency department (ED) visits involving zolpidem (commonly known as Ambien) overmedication almost doubled from 21,824 visits in...




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki